Our thorough analysis encompassing growth, profitability, financial stability, and valuation metrics uncovers fundamental ...

Kenvue (KVUE) reported $3.84 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 4%. EPS of $0.29 for the same period compares to $0.32 a year ago. The ...

Kenvue cut its annual sales forecast on Thursday, as the consumer health company undergoes a strategic review aiming to boost ...

(NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of ...

The Summit, N.J., drugmaker said Monday that both net and organic sales are likely to be down by low single-digit percentages from last year. It previously guided for net sales to grow 1% to 3%, and ...

Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago. These figures are ...

Kenvue forecast its annual profit below Wall Street estimates, as it undergoes a strategic review, which investors expect ...

Kenvue's Q2 2025 earnings call highlights leadership changes, strategic reviews, and a revised guidance reflecting a low single-digit sales decline.

Key Points Non-GAAP earnings per share of $0.29 in Q2 FY2025 beat expectations, but GAAP revenue missed estimates and GAAP net sales declined 4.0% from the prior year. Management lowered its FY2025 ...

Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...